-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $16

Benzinga·03/31/2026 13:53:15
Listen to the news
Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $11 to $16.